Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Medical Device Tax

After 2-Year Hiatus, 2.3 Percent Medical Device Tax Could Be Reinstated on January 1; Industry Launches Campaign

Washington, DC, August 15, 2017 — Bob Salsberg reports in The Washington Post that the industry that makes medical devices from artificial hips to miniature pumps for IV drips is looking for a fallback plan to permanently repeal a widely reviled sales tax that almost met its end in Republicans’ health care legislation.

The 2.3 percent medical device excise tax — one of several taxes and fees in the Affordable Care Act that pay for expanded insurance coverage — has been the subject of ferocious lobbying by manufacturers seeking its permanent death.

Yet for now it’s on track to be reinstated on Jan. 1 after a two-year hiatus, leaving industry leaders worried it will hurt employment and stifle development of innovative, even lifesaving products. Continue reading

Medical Device Group Launches Ad Campaign to Repeal Obamacare’s 2.3 Percent Excise Tax

Washington, DC, August 10, 2017 — Peter Sullivan reports in The Hill that the Advanced Medical Technology Association (AdvaMed) is launching a new advertising campaign to push lawmakers to repeal Obamacare’s tax on medical devices.

AdvaMed will be running the digital and social media ads in 15 states this month, pushing lawmakers to repeal the medical device tax when they return from recess in September.  Continue reading

MedTech Industry Lost Nearly 29,000 Jobs While Device Tax in Effect, U.S. Commerce Reports

Washington, DC, February 9, 2017 — The U.S. medical technology industry saw its jobs ranks fall by nearly 29,000 while the medical device excise tax was in effect, according to the latest figures from the U.S. Department of Commerce.

Specifically, from 2012 to 2015, the number of U.S. medtech jobs declined from 401,472 to 372,638 – a loss of 28,834 jobs or a 7.2 percent decrease for the time period.

“These numbers reveal just how devastating of an impact the device tax had on our industry and underscore the urgent need for permanent repeal,” said Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed). Continue reading

AdvaMed Survey Data Shows MedTech Industry Poised for Greater Investment and Growth with Full Device Tax Repeal

medical-device-tax-23Washington, DC, January 12, 2017 — Medical technology companies are leveraging the 2015 suspension of the medical device excise tax to expand their businesses and investments, according to a new survey from the Advanced Medical Technology Association (AdvaMed).

The study explored various impacts from the tax’s suspension — from job retention and creation to elevated R&D infusions — and suggests a broad range of strong economic activity. Industry analysts believe, however, greater economic growth would occur with permanent device tax repeal.

“Our members are bullish on future industry growth and job creation, as these numbers indicate,” said AdvaMed President and CEO Scott Whitaker. Continue reading

Congress Likely to Permanently Repeal Medical Device Tax Under President Trump

medical-device-tax-23Washington, DC, December 12, 2016 — Reuters reports that when Donald Trump takes over as president on January 20, one of the first business tax breaks he delivers is likely to go to the U.S. medical device industry.

Trump and U.S. lawmakers are likely to repeal the tax permanently, according to lawmakers, lobbyists and industry executives.

Tax cuts are Republican gospel, and Trump’s new Republican administration is widely expected to make them happen. Continue reading

HINJ Statement on Passage of the Omnibus Spending Package

hinj_logo_high_resNew Brunswick, NJ, December 18, 2015 — The HealthCare Institute of New Jersey (HINJ) congratulates Congress on the passage of legislation that includes several key provisions that will strengthen medical innovation in the United States.

The spending measure, which received bipartisan support, includes $2 billion in increased funding for the National Institutes of Health (NIH); a $133 million increase in funding for the Food and Drug Administration (FDA); a two-year suspension of the medical device excise tax; and makes permanent the Research & Development (R&D) tax credit. Continue reading

AdvaMed, MITA and MDMA Commend Congress for Including Suspension of the Medical Device Tax in Year-End Legislation

Capitol Dome flag faveWashington, DC, December 16, 2015 ― The Advanced Medical Technology Association (AdvaMed), the Medical Imaging & Technology Alliance (MITA) and the Medical Device Manufacturers Association (MDMA) today commended Congress for including suspension of the medical device excise tax in year-end legislation and urged its swift passage.

“We are extremely appreciative of the bipartisan efforts to include a two-year suspension of the medical device tax in the tax extenders legislation. Suspending the tax will be an important step in addressing the harmful effect it is having on research and development and continued medical progress.  On behalf of America’s medical technology companies, our employees and the patients we serve, we urge Congress to act swiftly on this legislation,” said AdvaMed Board Chairman Vincent A. Forlenza, chairman, CEO and president BD. Continue reading

AdvaMed Leadership Kicks-Off AdvaMed 2015 Conference in San Diego

AdvaMed 2015San Diego, CA, October 5, 2015 ― Advanced Medical Technology Association (AdvaMed) Board Chairman Vincent A. Forlenza, chairman, CEO and president BD, and Stephen J. Ubl, president and CEO of AdvaMed today kicked-off AdvaMed 2015 in San Diego, California.

Forlenza and Ubl launched the conference—the nation’s premier medical technology event—with an update on several key policy issues and an overview of two new studies demonstrating the value of advanced medical technology to the health system, to patients and to the broader economy. Continue reading

U.S. House Votes to Kill Obamacare’s 2.3 Percent Medical Device Tax

Washington, DC, June 19, 2015 The New York Times reported that the U.S. House of Representatives defied a White House veto threat and voted Thursday to abolish a tax on medical device makers as a group of Democrats uncharacteristically joined Republicans in moving to kill part of President Obama’s health care law.

Thursday’s 280-140 House vote was exactly the two-thirds margin that supporters would need to override a presidential veto.

The real suspense will come in the Senate, which voted overwhelmingly to repeal the levy in 2013, but in a nonbinding roll call lacking the political pressures of a veto showdown. Continue reading

House Committee Votes to Repeal Obamacare’s Medical Device Tax and IPAB

Washington, DC, June 3, 2015The Washington Post reports that the House Ways and Means Committee voted Tuesday — with a mostly party-line 25-14 vote—to repeal a 2.3 percent tax on many medical devices that helps pay for President Barack Obama’s health care overhaul.  The tax took effect in January 2013.

The Republicans say the levy costs jobs and stifles innovation.  On the other hand, most Democrats say those claims are exaggerations and complained that Republicans have offered no savings to cover the $24.4 billion in lost revenue the repeal would cost over the coming decade. Continue reading